4Suppliers
18Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Zai Lab Limited (ZLAB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

25Total relationships
2Distinct source URLs
5High confidence
0.698Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Zai Lab Limited Suppliers

TickerNameConfidenceEvidence
HALO Halozyme Therapeutics, Inc. 72% Reciprocal relationship from HALO graph: Reciprocal relationship from ZLAB graph: Reciprocal relationship from HALO graph: Reciprocal relationship from ZLAB graph: Reciprocal relationship from HALO g…
MGNX MacroGenics, Inc. 72% Reciprocal relationship from MGNX graph: es and clinical testing, and regulatory approval prior to commercial use. The future success of the Company is dependent on its ability to identify and develo…
PFE Pfizer Inc. 72% Reciprocal relationship from PFE graph: Item 1A. Risk Factors—Research and Development section. COLLABORATION AND CO-PROMOTION AGREEMENTS We use collaboration and/or co-promotion arrangements to enha…
VRTX Vertex Pharmaceuticals Incorporated 72% Reciprocal relationship from VRTX graph: f period $ $ $ Supplemental disclosure of cash flow information: Cash paid for income taxes $ $ $ Cash paid for interest $ $ $ Net payments due to CRISPR Ther…

Zai Lab Limited Customers

TickerNameConfidenceEvidence
FIVE-LARGEST-CUSTOMERS FIVE-LARGEST-CUSTOMERS 92% Our five largest customers accounted for approximately 32.4% and 35.0% of our total product revenue in 2024 and 2023, respectively
LARGEST-CUSTOMER LARGEST-CUSTOMER 92% As of March 31, 2026, our largest customer accounted for approximately 25% of our total accounts receivable collectively.
HALO Halozyme Therapeutics, Inc. 72% Reciprocal relationship from HALO graph: ds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefi…
AUST-PTY-LTD AUST-PTY-LTD 62% “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s…
F-11-ZAI-LAB-LIMITED F-11-ZAI-LAB-LIMITED 62% ated statements of operations. F-11 Zai Lab Limited Notes to the Consolidated Financial Statements For the Years Ended December 31, 2024, 2023, and 2022 (e) Cash, Cash Equivalents, and Restricted Cas…
F-12-ZAI-LAB-LIMITED F-12-ZAI-LAB-LIMITED 62% from product sales and represent amounts due from its customers. From January 1, 2020, the Company adopted the ASU 2016-13, Credit Losses, Measurement of Credit Losses on Financial Instruments. Accou…
F-13-ZAI-LAB-LIMITED F-13-ZAI-LAB-LIMITED 62% from product sales and represent amounts due from its customers. From January 1, 2020, the Company adopted the ASU 2016-13, Credit Losses, Measurement of Credit Losses on Financial Instruments. Accou…
F-16-ZAI-LAB-LIMITED F-16-ZAI-LAB-LIMITED 62% the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within th…
F-18-ZAI-LAB-LIMITED F-18-ZAI-LAB-LIMITED 62% product revenue, respectively for the same periods. Concentration of Credit Risk Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cas…
HONG-KONG-LIMITED HONG-KONG-LIMITED 62% “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s…
HUMAN-GENETIC-RESOURCES HUMAN-GENETIC-RESOURCES 62% “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s…
HUMAN-RESOURCES HUMAN-RESOURCES 62% linical studies, clinical trials, production and distribution, post-market studies, and the monitoring, reporting, and handling of adverse reactions in connection with pharmaceuticals. The marketing …
NOVO-HOLDINGS NOVO-HOLDINGS 62% ucture to support the sales of our commercial products. Our sales and marketing teams cover major medical centers across Greater China, and our commercial team has capabilities that cover the product…
SHANGHAI-CO-LTD SHANGHAI-CO-LTD 62% “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s…
SUZHOU-CO-LTD SUZHOU-CO-LTD 62% “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s…
TAIWAN-LIMITED TAIWAN-LIMITED 62% “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s…
US-LLC US-LLC 62% “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s…
ZHEJIANG-CO-LTD ZHEJIANG-CO-LTD 62% “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking s…

Zai Lab Limited Debt Obligations

InstrumentDescriptionConfidenceEvidence
ZLAB-DEBT Debt stack $238.1M 90% Market cache reports total debt of $238.1M.
ZLAB-DEBT-13765 Warrants outstanding: 1000000 90% xbrl warrant detail from xbrl 2017-12-31.
ZLAB-DEBT-13766 Xbrl Convertible 90% xbrl convertible detail from xbrl 2017-12-31.

Zai Lab Limited Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zai Lab Limited.

Zai Lab Limited Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Zai Lab Limited.

Zai Lab Limited Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
MGNX MacroGenics, Inc. 100.00 1 ['supplier']
MCK McKesson Corporation 100.00 2
VRTX Vertex Pharmaceuticals Incorporated 100.00 2 ['supplier']
ORKA Oruka Therapeutics, Inc. 100.00 2
PFE Pfizer Inc. 100.00 1 ['supplier']
AMPH Amphastar Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 50.00 2
CTMX CytomX Therapeutics, Inc. 50.00 2
CAH Cardinal Health, Inc. 50.00 2
ARVN Arvinas, Inc. 50.00 2
BNTX BioNTech SE 50.00 2
RLAY Relay Therapeutics, Inc. 50.00 2
SPRO Spero Therapeutics, Inc. 50.00 2
GILD Gilead Sciences, Inc. 50.00 2
HBIO Harvard Bioscience, Inc. 50.00 2
ESPR Esperion Therapeutics, Inc. 50.00 2
GNMSF Genmab A/S 50.00 2
INCY Incyte Corporation 50.00 2
NVAX Novavax, Inc. 50.00 2
CELC Celcuity Inc. 50.00 2
🔐
ZLAB
Unlock ZLAB Supply Chain Data
Verified relationships include:
HALOHalozyme Therapeutics, Inc.Supplier72%
MGNXMacroGenics, Inc.Supplier72%
FIVE-LARGEST-CUSTOMERSFIVE-LARGEST-CUSTOMERSCustomer92%
LARGEST-CUSTOMERLARGEST-CUSTOMERCustomer92%
+21 more relationships locked
Subscribe — View plans →